Evaluation of lead compounds in preclinical species is a prerequisite for the progression of drug candidates in the drug discovery and development process.
In vivo pharmacokinetic (PK) studies provide information on the changes in drug concentration with time, usually in blood or plasma, following dosing.  Data from animal PK studies is used by medicinal chemists to optimize compounds and by pharmacologists to design, interpret efficacy and toxicology studies, and link the observed PD effect to the concentration (PK/PD), as well as to predict the PK profile in humans.  Within the lead optimisation phase, the first PK studies are usually performed in rodents followed by non-rodents at later stages.
In addition to in vivo studies, at Fidelta we have the capability to ensure a range of services including bioanalytical method development, quantitative and qualitative analysis, vehicle assessment and stability testing, and pharmacokinetic calculations.


Fidelta provides both predesigned and
customizable studies with rapid turnaround
time and high quality.
These include:

Exploratory/Rapid PK
Basic PK parameters, Blood/Plasma
sampling, Cassette Dosing

Full PK profiling:
Bioavailability, Dose proportionality, Tissue
distribution, Brain-to-plasma ratio,
Bioequivalence, Single vs. multiple dosing,
Metabolite profiling

  Administration routes and sampling 
   Dosing routes:
      oral, intravenous (bolus and infusion), subcutaneous, intramuscular,
      intraperitoneal,intratracheal, intranasal, and intraduodenal
   Sample collection:
      Serial sampling: tail or saphenous vein;sampling from catheter
      Terminal sampling: cardiac puncture or arterial/vein sampling
      A variety of matrices can be collected:
        – Blood/plasma/serum
        – Tissues (e.g. liver, lung, brain, muscle, etc.)
        – Urine/faeces collection in metabolic cages.


Figures 1 & 2. Plasma concentration of a test compound following i.v. bolus and oral gavage administration in rat